JP2009509970A5 - - Google Patents

Download PDF

Info

Publication number
JP2009509970A5
JP2009509970A5 JP2008532483A JP2008532483A JP2009509970A5 JP 2009509970 A5 JP2009509970 A5 JP 2009509970A5 JP 2008532483 A JP2008532483 A JP 2008532483A JP 2008532483 A JP2008532483 A JP 2008532483A JP 2009509970 A5 JP2009509970 A5 JP 2009509970A5
Authority
JP
Japan
Prior art keywords
composition
mutant
antibody
mnn1
saccharomyces cerevisiae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/037302 external-priority patent/WO2007035930A2/en
Publication of JP2009509970A publication Critical patent/JP2009509970A/ja
Publication of JP2009509970A5 publication Critical patent/JP2009509970A5/ja
Pending legal-status Critical Current

Links

JP2008532483A 2005-09-22 2006-09-22 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法 Pending JP2009509970A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71995205P 2005-09-22 2005-09-22
PCT/US2006/037302 WO2007035930A2 (en) 2005-09-22 2006-09-22 Glycosylated polypeptides produced in yeast mutants and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2009509970A JP2009509970A (ja) 2009-03-12
JP2009509970A5 true JP2009509970A5 (cg-RX-API-DMAC7.html) 2009-11-05

Family

ID=37889571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008532483A Pending JP2009509970A (ja) 2005-09-22 2006-09-22 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法

Country Status (6)

Country Link
US (1) US8202523B2 (cg-RX-API-DMAC7.html)
EP (1) EP1934605B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009509970A (cg-RX-API-DMAC7.html)
CN (1) CN101313216A (cg-RX-API-DMAC7.html)
CA (1) CA2623197A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007035930A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601797A1 (en) * 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
US20110117601A1 (en) * 2007-08-31 2011-05-19 Markus Haberger Glycosylation Profile Analysis
EP2918606B1 (en) * 2008-12-04 2018-07-11 Korea Research Institute of Bioscience and Biotechnology Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins
US20100291540A1 (en) * 2009-05-12 2010-11-18 National Tsing Hua University Carbohydrate binding module and use thereof
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
CN101914458B (zh) * 2010-02-09 2013-03-13 北京万特尔生物制药有限公司 白假丝酵母(甘露糖蛋白质复合体)菌毛株
BR112013007616B1 (pt) 2010-09-29 2023-01-24 Oxyrane Uk Limited Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
JP6131190B2 (ja) 2010-09-29 2017-05-17 オキシレイン ユーケー リミテッド リン酸化ｎ−グリカンの脱マンノシル化
US8986956B2 (en) 2010-11-04 2015-03-24 Korea Research Institute Of Bioscience And Biotechnology Method for producing human epidermal growth factor in large volume from yeast
US8396871B2 (en) 2011-01-26 2013-03-12 DiscoverReady LLC Document classification and characterization
US9667514B1 (en) 2012-01-30 2017-05-30 DiscoverReady LLC Electronic discovery system with statistical sampling
US10467252B1 (en) 2012-01-30 2019-11-05 DiscoverReady LLC Document classification and characterization using human judgment, tiered similarity analysis and language/concept analysis
CA2867237C (en) 2012-03-15 2024-01-02 Wouter Vervecken Methods and materials for treatment of pompe's disease
US20150299690A1 (en) * 2012-12-10 2015-10-22 Bo Jiang Engineered lower eukaryotic host strains deficient in grr1 activity for recombinant protein
US9677105B2 (en) * 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP3077517B1 (en) * 2013-12-02 2018-10-17 DSM IP Assets B.V. Ice structuring protein
CN104725484B (zh) * 2013-12-19 2018-03-13 中国科学院微生物研究所 一种糖基化多肽及其制备方法和其应用
KR101750888B1 (ko) * 2014-09-23 2017-06-26 한국생명공학연구원 YlMpo1 과발현을 이용한 만노스인산화 증대 방법
MX2017009253A (es) * 2015-01-16 2017-10-12 Alder Biopharmaceuticals Inc Anticuerpos antiglicoproteina y usos de los mismos.
CN113201054B (zh) * 2021-05-21 2022-07-05 华南农业大学 蛋白FoUPE1在调控香蕉枯萎病菌致病力中的应用
CN115160417B (zh) * 2022-06-24 2023-06-02 西南大学 盔形毕赤酵母Glyco_hydro类分泌蛋白及其应用
CN116590371B (zh) * 2023-07-13 2023-10-17 智享生物(苏州)有限公司 一种降低中华仓鼠卵巢细胞中抗体高甘露糖型的细胞培养方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
DE3224788A1 (de) 1981-07-17 1983-02-03 South African Inventions Development Corp., Scientia, Pretoria,Transvaal Traegergebundenes immunogenes material
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5266478A (en) 1987-05-29 1993-11-30 Tanox Biosystems, Inc. Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
US5854400A (en) 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
EP0295803B1 (en) 1987-05-29 1993-11-03 Shuzo Matsushita Monoclonal antibodies
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5763160A (en) 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5298419A (en) 1988-03-31 1994-03-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5614612A (en) 1990-03-09 1997-03-25 Haigwood; Nancy L. Purified gp120 compositions retaining natural conformation
US5798251A (en) 1990-05-29 1998-08-25 Cedars-Sinai Medical Center Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
US5914109A (en) 1990-06-15 1999-06-22 New York University Heterohybridomas producing human monoclonal antibodies to HIV-1
US5712373A (en) 1990-07-02 1998-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992007878A1 (en) 1990-10-26 1992-05-14 The Public Health Research Institute Of The City Of New York, Inc. Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5696238A (en) 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
WO1993012232A1 (en) 1991-12-10 1993-06-24 Dana Farber Cancer Institute Reactive neutralizing human anti-gp120 recombinant antibody, dna coding the same and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6103238A (en) 1992-03-13 2000-08-15 President And Fellows Of Harvard College Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
DE4301932A1 (de) 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh Hefewirtsstämme mit Defekten in der N-Glycosylierung
DE69433422T2 (de) 1993-03-11 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Monoklonaler anti-hiv antikörper
DK0699077T3 (da) 1993-05-07 2002-01-21 Bio Merieux Inc Immunogele HIV-komplekser
CA2156718A1 (en) 1993-12-23 1995-06-29 Bruno Gander Immunological response potentiation process
ATE177843T1 (de) 1994-01-19 1999-04-15 Us Health Peptomere mit erhöhter immunogenizität
US5559010A (en) * 1994-04-04 1996-09-24 The Regents Of The University Of California Nutrient regulated gene expression systems
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
EP0871485B1 (en) 1995-07-21 2007-02-21 University Of Nebraska Board Of Regents COMPOSITIONS AND METHODS FOR CATALYZING HYDROLYSIS OF HIV gp120
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP2767401B2 (ja) 1995-11-17 1998-06-18 工業技術院長 酵母のマンノース−１−リン酸転移酵素遺伝子およびこれを利用するマンノース−１−リン酸含有酸性糖鎖の製造方法
ES2277339T3 (es) 1995-11-30 2007-07-01 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vacuna con adyuvante de aceite y metodo para su preparacion.
AU1834197A (en) 1996-01-30 1997-08-22 National Institutes Of Health, The Cells expressing both human cd4 and cxcr4
US6713069B1 (en) 1996-04-16 2004-03-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100637410B1 (ko) * 1999-08-19 2006-10-23 기린 비루 가부시키가이샤 신규한 효모 변이주 및 포유류형 당쇄를 함유하는당단백질의 제조방법
AU7089600A (en) 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
JP3905695B2 (ja) * 1999-08-31 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 分裂酵母の糖転移酵素遺伝子ｏｃｈ１
US6391567B1 (en) 2000-03-02 2002-05-21 New York University Identifying compounds inhibiting DC-sign facilitation of HIV into cells
WO2001088143A1 (en) * 2000-05-17 2001-11-22 Mitsubishi Pharma Corporation Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
EP2028275A3 (en) 2000-06-30 2009-05-06 VIB vzw Protein glycosylation modification in pichia pastoris
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP4464269B2 (ja) * 2002-04-26 2010-05-19 協和発酵キリン株式会社 哺乳類型糖鎖生産メチロトロフ酵母
US7252933B2 (en) * 2002-06-26 2007-08-07 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in methylotrophic yeast
US7250251B2 (en) 2002-09-09 2007-07-31 The J. David Gladstone Institutes Virion-based fusion assay
CA2504755C (en) * 2002-10-11 2010-12-14 University Of Maryland Biotechnology Institute Carbohydrate-based synthetic vaccines for hiv
AU2003301804A1 (en) 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
EP1417965A1 (en) 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
WO2004050711A2 (en) * 2002-12-03 2004-06-17 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
EP1696864B1 (en) * 2003-12-24 2014-11-12 GlycoFi, Inc. Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins
CA2601797A1 (en) * 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
US7728106B2 (en) * 2005-07-01 2010-06-01 University Of Maryland Biotechnology Institute HIV-1 glycopeptides and derivatives; preparation and applications thereof
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
CA2647632C (en) * 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
JP5967861B2 (ja) * 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化

Similar Documents

Publication Publication Date Title
Hoyer et al. The ALS5 gene of Candida albicans and analysis of the Als5p N‐terminal domain
Behrens et al. Structural principles controlling HIV envelope glycosylation
EP1934605B1 (en) Glycosylated polypeptides produced in yeast mutants and methods of use thereof
Schreuder et al. Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine
Temme et al. High temperature SELMA: evolution of DNA-supported oligomannose clusters which are tightly recognized by HIV bnAb 2G12
JP2014507144A5 (ja) 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
Cheng et al. Identification of Candida albicans genes induced during thrush offers insight into pathogenesis
JP2010502207A5 (cg-RX-API-DMAC7.html)
Hyakumura et al. Modification of asparagine-linked glycan density for the design of hepatitis B virus virus-like particles with enhanced immunogenicity
Guo et al. Biological and molecular characteristics of a novel partitivirus infecting the edible fungus Lentinula edodes
WO2007109564A3 (en) Yeast cell particles as oral delivery vehicles for antigens
TW201920236A (zh) 用於對ｈｂｖ產生免疫反應之類病毒粒子
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
Zambonelli et al. Generation and characterization of a bivalent HIV-1 subtype C gp120 protein boost for proof-of-concept HIV vaccine efficacy trials in southern Africa
WO2006002079A8 (en) Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
AU2001258985A1 (en) A recombinant yeast for lignocellulose raw materials
Liu et al. Disruption of the OCH1 and MNN1 genes decrease N-glycosylation on glycoprotein expressed in Kluyveromyces lactis
Yu et al. Poxvirus structural biology for application to vaccine design
KR20180038557A (ko) 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도
JP2023503963A5 (cg-RX-API-DMAC7.html)
JP2022166240A (ja) エボラ感染症の処置用のモノクローナル抗体およびカクテル
CN101440372A (zh) 一种18型人乳头状瘤病毒主要衣壳蛋白l1基因
CN101440371B (zh) 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
Kim et al. An application of protein microarray in the screening of monoclonal antibodies against the oyster mushroom spherical virus
CN116925195A (zh) 一种基于新型冠状病毒的mRNA疫苗